Microcap Ledger Lexicon Pharmaceuticals, Inc. $LXRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- The Woodlands, TX
- Fiscal year end
- December 31
- Shares outstanding
- 444,955,934 [10-Q 2026-08-06]
What the company doesAI summary of filing
Lexicon Pharmaceuticals is a biopharmaceutical company that develops small molecule drug candidates and commercializes approved medicines. The company's primary focus is on sotagliflozin, which is approved and commercialized as INPEFA for heart failure and is in late-stage clinical development for hypertrophic cardiomyopathy and under regulatory review for type 1 diabetes; pilavapadin for neuropathic pain, currently in Phase 2 trials; and LX9851 for obesity, which has been licensed to Novo Nordisk for development and commercialization. Lexicon generates revenue from product sales of INPEFA, which it distributes through wholesalers and mail order pharmacies, and from milestone and royalty payments from its licensing agreements with Novo Nordisk and Viatris. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $21.79M | −$32.82M | −$23.92M | $40.92M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $49.80M | −$50.34M | −$67.85M | $34.33M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $31.08M | −$200.40M | −$178.78M | $66.66M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$11.96M
- Cash runway Estimate
- ~10.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 361,492,295 | [10-Q 2024-11-13] |
| 2025-02-28 | 361,492,295 | [10-K 2025-03-07] |
| 2025-05-09 | 363,178,000 | [10-Q 2025-05-14] |
| 2025-08-01 | 363,398,860 | [10-Q 2025-08-06] |
| 2025-11-04 | 363,398,680 | [10-Q 2025-11-06] |
| 2026-03-04 | 423,680,611 | [10-K 2026-03-05] |
| 2026-05-04 | 444,196,390 | [10-Q 2026-05-07] |
| 2026-08-03 | 444,955,934 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-08-06; declared effective 2026-08-14 [S-3 2026-08-06]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Sullivan Diane E. | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Sobecki Christopher J | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Cheung Ivan | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Barker Sam L | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Amouyal Philippe | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-06-03 | Debbane Raymond | exercise | 89,312 | — | [4 2026-06-04] |
| 2026-04-30 | Artal Participations S.A R.L. | exercise | 20,421,735 | — | [4 2026-05-08] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-06 | S-3 | Registration statement |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Results of operations |
| 2026-05-08 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-05-06 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-04-30 | 8-K | Material agreement entered; Unregistered sale of equity; Charter, bylaws or fiscal year change |
| 2026-03-16 | DEF 14A | Proxy statement |
| 2026-03-05 | 10-K | Annual report |
| 2026-03-05 | 8-K | Results of operations |
Alerts for $LXRX
Email me when Lexicon Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.